AEGiS-IRIN: Cost of HIV/Aids Drugs Reduced UN Integrated Regional Information NetworkImportant note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
Click here to return to UN Integrated Regional Information Network main menu
DonateNow


Cost of HIV/Aids Drugs Reduced

Integrated Regional Information Networks - September 11, 2002


The cost of HIV/AIDS drugs in the Central African Republic (CAR) has been reduced from 600,000 CFA francs (US $1,000) to 22,815 CFA francs ($37) for some patients, following negotiations with foreign pharmaceutical laboratories.

The move, facilitated by UNAIDS, came during an HIV/AIDS triple therapy programme, officially inaugurated on 4 September by Health Minister Joseph Kalite. However, a quantity of medication sufficient for only 100 people will be made available during the first year, in accordance with an agreement reached with pharmaceutical companies.

"We signed an accord with Merck Sharp and Domes [USA] in July 2001, with Smith Kline [UK] and CIPLA (India) in October 2001," Dr Jean Bertrand Wata, Director of the Tripletherapy Centre and national coordinator of HIV/AIDS drugs access programme, told IRIN.

He added that during the first year, the Tripletherapy Centre would take care of 100 patients who would be chosen on the basis of very strict biological and clinical criteria, as determined by specialised medical doctors.

According to a ministerial decree, only 11 doctors in CAR are currently authorised to prescribe HIV/AIDS drugs, because of the specific training required. Wata said the training programme for HIV/AIDS drugs administration would be extended to doctors in rural areas very soon.

Acknowledging that the cost of the treatment was still well out of reach of the average CAR citizen, Wata told IRIN his centre would seek funding from the government in an effort to further reduce the cost.

CAR is the most severely HIV/AIDS-affected nation in the central African subregion and the 10th most affected in the world, with 12 percent of its population HIV-positive.
020911
IR020906


Copyright © 2002 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980 – 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .